These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10353890)

  • 21. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis.
    Frøholm LO; Caugant DA; Holten E; Høiby EA; Rosenqvist E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):139-43; discussion 144-6. PubMed ID: 1812428
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine research: new vaccines and evidence of vaccine safety.
    Commun Dis Rep CDR Wkly; 1999 May; 9(19):167, 170. PubMed ID: 10334064
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.
    Perkins BA; Jonsdottir K; Briem H; Griffiths E; Plikaytis BD; Hoiby EA; Rosenqvist E; Holst J; Nokleby H; Sotolongo F; Sierra G; Campa HC; Carlone GM; Williams D; Dykes J; Kapczynski D; Tikhomirov E; Wenger JD; Broome CV
    J Infect Dis; 1998 Mar; 177(3):683-91. PubMed ID: 9498448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control.
    Can Fam Physician; 1994 Dec; 40():2121-3. PubMed ID: 7888825
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the class-1 outer membrane protein from B:15:P1.16 Neisseria meningitidis strains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway.
    Brooks JL; Rosenqvist E; Bjune G; Lambden PR; Heckels JE
    Microb Pathog; 1994 Dec; 17(6):425-30. PubMed ID: 7752883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of meningococcal vaccines with emphasis on possible immunoprophylaxis of group B disease.
    Frøholm LO
    NIPH Ann; 1980 Dec; 3(2):67-74. PubMed ID: 6784045
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of meningococcal disease by group C polysaccharide vaccine.
    Artenstein MS; Gold R; Zimmerly JG; Wyle FA; Schneider H; Harkins C
    N Engl J Med; 1970 Feb; 282(8):417-20. PubMed ID: 4983754
    [No Abstract]   [Full Text] [Related]  

  • 30. Postgenomics of Neisseria meningitidis for vaccines development.
    Bernardini G; Braconi D; Martelli P; Santucci A
    Expert Rev Proteomics; 2007 Oct; 4(5):667-77. PubMed ID: 17941821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
    Fredriksen JH; Rosenqvist E; Wedege E; Bryn K; Bjune G; Frøholm LO; Lindbak AK; Møgster B; Namork E; Rye U
    NIPH Ann; 1991 Dec; 14(2):67-79; discussion 79-80. PubMed ID: 1812438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.
    Høiby EA; Bjune G; Frøholm LO; Eng J; Halstensen A; Rosenqvist E; Rønnild E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):107-21; discussion 121-3. PubMed ID: 1812424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production and control of Neisseria meningitidis vaccines.
    Frasch CE
    Adv Biotechnol Processes; 1990; 13():123-45. PubMed ID: 2110462
    [No Abstract]   [Full Text] [Related]  

  • 34. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 35. [Vaccination Project-88. New Norwegian vaccine against type B meningitis--what happened?].
    Rød KA
    Fag Tidsskr Sykepleien; 1990 Jan; 78(1):27-31. PubMed ID: 2109367
    [No Abstract]   [Full Text] [Related]  

  • 36. Meningococcal disease falls in vaccine recipients.
    Commun Dis Rep CDR Wkly; 2000 Apr; 10(15):133, 136. PubMed ID: 10793463
    [No Abstract]   [Full Text] [Related]  

  • 37. Serogroup B meningococcal disease: new outbreaks, new strategies.
    Wenger JD
    JAMA; 1999 Apr; 281(16):1541-3. PubMed ID: 10227326
    [No Abstract]   [Full Text] [Related]  

  • 38. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.
    Nøkleby H; Feiring B
    NIPH Ann; 1991 Dec; 14(2):95-101; discussion 101-2. PubMed ID: 1812440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Systemic meningococcal disease in the Norwegian Army].
    Djupesland P; Bjurne G; Aanonsen NO; Borchgrevink HM; Mundal R; Høiby EA
    Nord Med; 1990; 105(6-7):179-81. PubMed ID: 2367188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Universal vaccination against group C meningococci and pneumococci; advice from the Health Council of the Netherlands].
    van Furth AM; Vandenbroucke-Grauls CM
    Ned Tijdschr Geneeskd; 2002 May; 146(20):932-3. PubMed ID: 12051059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.